MBX
HealthcareMBX Biosciences, Inc. Common Stock · Biotechnology · $1B
What is MBX Biosciences, Inc. Common Stock?
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Founded in 2018 and headquartered in Carmel, Indiana, the company is building a pipeline targeting conditions with limited treatment options.
MBX Biosciences discovers and develops long-acting peptide prodrug therapies designed to treat chronic endocrine and metabolic conditions. Its lead candidate targets chronic hypoparathyroidism, a rare hormone disorder. A second program addresses post-bariatric hypoglycemia, a complication arising from weight-loss surgery. The company also has an obesity-focused candidate in early-stage development, positioning it within the fast-growing GLP-1 therapeutic space. Revenue is not yet generated — the company is pre-commercial and funded through capital raises.
MBX Biosciences was founded in 2018 and is based in Carmel, Indiana.
- MBX 2109 — long-acting parathyroid hormone prodrug for hypoparathyroidism (Phase 2)
- MBX 1416 — GLP-1 receptor antagonist for post-bariatric hypoglycemia (Phase 1)
- MBX 4291 — GLP-1 and GIP co-agonist prodrug targeting obesity (IND-enabling stage)
- Precision peptide prodrug platform for endocrine disorders
Is MBX a Good Stock to Buy?
UQS Score rates MBX as Poor overall, reflecting the early-stage nature of the business across most evaluated dimensions.
The Risk pillar stands out as the relative bright spot in MBX's profile — a meaningful distinction for a pre-revenue clinical-stage company where capital structure and cash runway matter most to near-term survival.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial products, no revenue, and an unproven competitive position. Valuation is rated Elevated, suggesting the market may already be pricing in optimistic clinical outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MBX pay dividends?
No — MBX Biosciences, Inc. Common Stock does not currently pay a dividend.
MBX Biosciences does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials, research operations, and pipeline advancement. Investors in pre-commercial biotechs generally seek returns through potential pipeline success and share price appreciation rather than income distributions.
When does MBX report earnings?
MBX Biosciences reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, MBX's quarterly reports center on cash position, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Key updates typically include pipeline milestones and commentary on runway.
For the most current quarterly results and clinical updates, visit MBX Biosciences' investor relations page directly.
MBX Price History
+27.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in MBX Biosciences, Inc. Common Stock?
Based on MBX Biosciences, Inc. Common Stock's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MBX Long-term Outlook
MBX's Growth pillar is rated Weak, reflecting the absence of commercial revenue and the binary nature of clinical-stage drug development. The path to value creation depends almost entirely on clinical trial outcomes for MBX 2109 and MBX 1416. The Risk pillar rating of Good provides some reassurance around near-term financial stability, but the Elevated Valuation rating suggests limited margin of safety if trial results disappoint. Progress in the obesity pipeline via MBX 4291 could become a longer-term catalyst given sector tailwinds.
Growth drivers
- Positive Phase 2 data for MBX 2109 in chronic hypoparathyroidism
- Expanding GLP-1 pipeline addressing large metabolic disorder markets
- Obesity-focused MBX 4291 advancing toward clinical trials
Key risks
- Clinical trial failure or delays across any pipeline program
- Elevated valuation leaves little buffer for negative data readouts
- Ongoing cash burn with no commercial revenue to offset expenses
MBX vs Peers
MBX Biosciences operates in a competitive clinical-stage biopharma landscape alongside other specialty and rare-disease focused companies.
GH Research focuses on psychedelic-derived therapies for treatment-resistant depression, targeting a distinct therapeutic area from MBX's endocrine and metabolic focus.
Biohaven pursues a broader pipeline across neurological and rare diseases, giving it a more diversified clinical profile compared to MBX's peptide-centric approach.
Xeris has commercial-stage products in endocrinology, including glucagon therapies, making it a more mature peer to MBX's pre-commercial pipeline.
Frequently Asked Questions
What does MBX Biosciences do?
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide prodrug therapies for endocrine and metabolic disorders. Its pipeline targets chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity. The company has no commercial products yet and is funded through capital markets while advancing its candidates through clinical trials.
Does MBX pay dividends?
MBX Biosciences does not pay a dividend. As a pre-revenue clinical-stage company, it directs all capital toward research and clinical development. Dividend payments are not typical for early-stage biotechs, where the investment thesis centers on pipeline progress rather than income.
When does MBX report earnings?
MBX Biosciences reports on a quarterly cadence standard for US-listed companies. Because it is pre-commercial, reports focus on cash runway and clinical milestones rather than revenue. Check the company's investor relations page for the most current schedule and recent filings.
Is MBX a good stock to buy?
UQS Score rates MBX as Poor overall, driven by Weak ratings across Quality, Moat, and Growth — consistent with a pre-revenue clinical-stage company. The Risk pillar is rated Good, which is a relative positive. Whether MBX fits a portfolio depends on an investor's risk tolerance and view on clinical trial outcomes. See the full UQS breakdown for more detail.
Is MBX overvalued?
UQS Score's Valuation pillar for MBX is rated Elevated, suggesting the current market price may reflect optimistic assumptions about clinical success. For pre-commercial biotechs, valuation is inherently speculative and tied to pipeline probability. The full valuation metrics are available to UQS Pro members.
How does MBX compare to its competitors?
Among clinical-stage peers, MBX is differentiated by its peptide prodrug platform and focus on endocrine disorders. Xeris Biopharma has already reached commercial stage in endocrinology, while Biohaven and GH Research pursue different therapeutic areas. MBX's pipeline is earlier-stage than most peers, which increases both risk and potential upside.
What is MBX's market cap bracket?
MBX Biosciences is classified as a small-cap company. Small-cap biotechs at the clinical stage typically carry higher volatility than large-cap peers, as their valuations are heavily influenced by binary clinical trial events rather than steady revenue streams.
Who founded MBX Biosciences?
MBX Biosciences was founded in 2018 and is headquartered in Carmel, Indiana. For detailed founding history and leadership background, the company's official website and SEC filings provide the most accurate and up-to-date information.
Is MBX a long-term quality investment?
As a long-term quality indicator, UQS Score rates MBX as Poor, reflecting early-stage weaknesses across most pillars. Long-term quality typically requires demonstrated profitability, durable competitive advantages, and consistent growth — none of which MBX has established yet. Clinical success could change this profile materially over time.
What is MBX Biosciences' main competitive advantage?
MBX's differentiation lies in its precision peptide prodrug platform, which is designed to enable long-acting formulations of hormone-based therapies. This approach targets conditions — like chronic hypoparathyroidism — that have few approved treatment options. However, the Moat pillar is currently rated Weak, as the platform remains unproven commercially.
What sector does MBX belong to?
MBX Biosciences operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It focuses on endocrine and metabolic disorders, placing it adjacent to the rapidly growing GLP-1 and obesity therapeutics space, though its programs are at earlier development stages than leading commercial players.
Unlock Full MBX Biosciences Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access detailed financial metrics and trend data
- ✓Compare MBX against clinical-stage peers side by side
- ✓See the complete Risk and Valuation breakdown
- ✓Get alerts when MBX's UQS Score changes
- ✓Full analyst-grade view available to Pro members
Pro Analysis
MBX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 9, 2026 | 13.4 | 0.0 | 11.0 | 0.0 | 71.0 | 0.0 | +0.5 |
| Apr 14, 2026 | 12.9 | 0.0 | 11.0 | 0.0 | 68.0 | 0.0 | -9.8 |
| Apr 13, 2026 | 22.7 | 0.0 | 50.0 | 0.0 | 68.0 | 0.0 | +9.8 |
| Apr 2, 2026 | 12.9 | 0.0 | 11.0 | 0.0 | 68.0 | 0.0 | — |
MBX — Pillar Breakdown
Quality
— 0.0/100 (25%)MBX Biosciences, Inc. Common Stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)MBX Biosciences, Inc. Common Stock faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.0/100 (15%)MBX Biosciences, Inc. Common Stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)MBX Biosciences, Inc. Common Stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)MBX Biosciences, Inc. Common Stock operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MBX.
Score Composition
Financial Data
More Stock Analysis
How is the MBX UQS Score Calculated?
The UQS (Unified Quality Score) for MBX Biosciences, Inc. Common Stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses MBX Biosciences, Inc. Common Stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether MBX Biosciences, Inc. Common Stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.